Eliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Large Growth in Short Interest

Eliem Therapeutics, Inc. (NASDAQ:ELYMGet Free Report) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 13,000 shares, an increase of 19.3% from the February 29th total of 10,900 shares. Based on an average daily volume of 6,800 shares, the short-interest ratio is presently 1.9 days. Approximately 0.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BML Capital Management LLC lifted its stake in Eliem Therapeutics by 12.5% in the fourth quarter. BML Capital Management LLC now owns 2,180,000 shares of the company’s stock worth $5,886,000 after acquiring an additional 241,737 shares during the period. Driehaus Capital Management LLC increased its holdings in shares of Eliem Therapeutics by 20.3% during the second quarter. Driehaus Capital Management LLC now owns 810,593 shares of the company’s stock valued at $2,270,000 after acquiring an additional 136,909 shares in the last quarter. Silverarc Capital Management LLC increased its holdings in shares of Eliem Therapeutics by 1.7% during the second quarter. Silverarc Capital Management LLC now owns 494,089 shares of the company’s stock valued at $1,383,000 after acquiring an additional 8,134 shares in the last quarter. Vanguard Group Inc. increased its holdings in Eliem Therapeutics by 12.9% in the 3rd quarter. Vanguard Group Inc. now owns 309,821 shares of the company’s stock worth $815,000 after buying an additional 35,304 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Eliem Therapeutics in the 2nd quarter worth about $272,000. Institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Price Performance

Shares of NASDAQ ELYM opened at $2.74 on Friday. Eliem Therapeutics has a one year low of $2.34 and a one year high of $3.72. The firm’s 50 day simple moving average is $2.73 and its two-hundred day simple moving average is $2.67. The stock has a market capitalization of $75.54 million, a P/E ratio of -1.86 and a beta of 0.50.

About Eliem Therapeutics

(Get Free Report)

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.

Featured Articles

Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.